Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 6, 1999, Pages 507-515

  Kalemkerian, Gregory P ^a,b   Ou, Xiaolan ^c   Adil, Mohammed R ^c   Rosati, Rita ^d   Khoulani, M Monir ^c   Madan, Shashi K ^b   Pettit, George R ^e  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c Barbara Ann Karmanos Cancer Inst ^*  (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Dolastatin; Experimental therapeutics; Lung cancer; Xenografts

Indexed keywords

DOLASTATIN 10; PROTEIN BCL 2;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; DOSE RESPONSE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; FLUORESCENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032950658     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050931     Document Type: Article

References (23)

1. Bagniewski PG, Reid JM, Pitot HC, Sloan JA, Ames MM (1997) Pharmacokinetics of dolastatin 10 in adult patients with solid tumors. Proc Am Assoc Cancer Res 38: 221
2. Bai R, Pettit GR, Hamel E (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents. J Biol Chem 28: 17141
3. Beckwith M, Urba WJ, Longo DL (1993) Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85: 483
4. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G (1994) Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 145: 1036
5. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM (1996) Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res 56: 1851
6. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DGI, Higgs PI, Neckers L, Fojo T (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57: 130
7. Fisher DE (1995) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539
8. Haldar S, Jena N, Croce CM (1995) Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507
9. Haldar S, Chintapalli J, Croce C (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253
10. Haldar S, Basu A, Croce C (1997) Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229
11. Hu ZB, Gignac SM, Quentmeier H, Pettit GR, Drexler HG (1993) Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leuk Res 17: 333
12. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y (1994) Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54: 6
13. Keith FJ, Bradbury DA, Zhu YM, Russell NH (1995) Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML to Ara-C. Leukemia 9: 131
14. May WS, Tyler G, Ito T, Armstrong DK, Qatsha KA, Davidson NE (1994) Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2α in association with suppression of apoptosis. J Biol Chem 269: 26865
15. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Ohta S, Saijo N (1993) Apoptosis of lung cancer cells caused by some anti-cancer agents is inhibited by bcl-2. Biochem Biophys Res Commun 192: 30
16. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boetner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109: 6883
17. Reed JC (1995) Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9: 451
18. Tran HT, Newman RA, Beck DE, Huie R, Abbruzzese JL, Madden T (1997) A phase I, pharmacokinetic/pharmacodynamic study of dolastatin-10 in adult patients with advanced solid tumors. Proc Am Assoc Cancer Res 38: 306
19. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440
20. Walker C, Robertson L, Myskow M, Dixon G (1995) Expression of the bcl-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 72: 164
21. Waud WR, Dykes DJ, Pettit GR, Plowman J (1993) Preclinical antitumor activity of dolastatin 10. Proc Am Assoc Cancer Res 34: 383
22. Winterhalter BR, Berger DP Pettit GR, Fiebig HH (1991) Cytotoxicity of dolastatin 10, dolastatin 15 and dolastatin K333 in human tumor xenografts in vitro. Proc Am Assoc Cancer Res 32: 402
23. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U (1997) Induction of apoptosis in small-cell lung cancer by an antisense oligonucleotide targeting the bcl-2 coding sequence. J Natl Cancer Inst 89: 1027